Related references
Note: Only part of the references are listed.Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
Paul W. Noble et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
Steven D. Nathan et al.
THORAX (2016)
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
Lisa Lancaster et al.
BMJ OPEN RESPIRATORY RESEARCH (2016)
Pirfenidone exhibits cardioprotective effects by regulating myocardial fibrosis and vascular permeability in pressure-overloaded hearts
Kiyoshi Yamagami et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2015)
Pharmacokinetic evaluation of tissue distribution of pirfenidone and its metabolites for idiopathic pulmonary fibrosis therapy
Kohei Togami et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2015)
Getting to the Heart of the Matter New Insights Into Cardiac Fibrosis
Andrew Leask
CIRCULATION RESEARCH (2015)
Combination therapy in idiopathic pulmonary fibrosis: the way ahead will be hard
Athol Wells
EUROPEAN RESPIRATORY JOURNAL (2015)
A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials
Harold R. Collard et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy
P. Spagnolo et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
Vincent Cottin et al.
EUROPEAN RESPIRATORY REVIEW (2015)
Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
Ulrich Costabel et al.
ADVANCES IN THERAPY (2014)
Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts
Enrico Conte et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
Antiproteinuric effect of pirfenidone in a rat model of anti-glomerular basement membrane glomerulonephritis
Koji Takakura et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Risk prediction and end-points in idiopathic pulmonary fibrosis: one step at a time
Christopher J. Ryerson
EUROPEAN RESPIRATORY JOURNAL (2014)
Potential approaches to reverse or repair renal fibrosis
Desiree Tampe et al.
NATURE REVIEWS NEPHROLOGY (2014)
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Talmadge E. King et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Pirfenidone in Idiopathic Pulmonary Fibrosis: Real-Life Experience from a German Tertiary Referral Center for Interstitial Lung Diseases
Ute Oltmanns et al.
RESPIRATION (2014)
Real world experiences: Pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis
Nazia Chaudhuri et al.
RESPIRATORY MEDICINE (2014)
Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis
Dominique Valeyre et al.
RESPIROLOGY (2014)
Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11
Ganesh Raghu et al.
LANCET RESPIRATORY MEDICINE (2014)
Combination therapy: the future of management for idiopathic pulmonary fibrosis?
Wim A. Wuyts et al.
LANCET RESPIRATORY MEDICINE (2014)
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
William D. Travis et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Possible Involvement of Pirfenidone Metabolites in the Antifibrotic Action of a Therapy for Idiopathic Pulmonary Fibrosis
Kohei Togami et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2013)
Pirfenidone Attenuates Cardiac Fibrosis in a Mouse Model of TAC-Induced Left Ventricular Remodeling by Suppressing NLRP3 Inflammasome Formation
Yongliang Wang et al.
CARDIOLOGY (2013)
A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer
Carlo Vancheri et al.
EUROPEAN RESPIRATORY JOURNAL (2013)
Estimating Covariate-Adjusted Log Hazard Ratios in Randomized Clinical Trials Using Cox Proportional Hazards Models and Nonparametric Randomization Based Analysis of Covariance
Benjamin R. Saville et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2013)
Idiopathic Pulmonary Fibrosis: Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2012)
The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities
Stuart J. Pocock et al.
EUROPEAN HEART JOURNAL (2012)
Prednisone, Azathioprine, and N-Acetylcysteine for Pulmonary Fibrosis
Ganesh Raghu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Hot off the breath: Mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good
Athol U. Wells et al.
THORAX (2012)
Pirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells
Keiko Hisatomi et al.
BMC PULMONARY MEDICINE (2012)
An Official ATS/ERSARS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin αvβ8-mediated activation of TGF-β
Hideya Kitamura et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Pirfenidone for idiopathic pulmonary fibrosis
Demosthenes Bouros
LANCET (2011)
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Paul W. Noble et al.
LANCET (2011)
Antifibrotic activities of pirfenidone in animal models
C. J. Schaefer et al.
EUROPEAN RESPIRATORY REVIEW (2011)
Pirfenidone in idiopathic pulmonary fibrosis
H. Taniguchi et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias
Duy T. Nguyen et al.
HEART RHYTHM (2010)
Pirfenidone Is Renoprotective in Diabetic Kidney Disease
Satish P. RamachandraRao et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults
C. M. Rubino et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2009)
Pirfenidone Inhibits T-Cell Activation, Proliferation, Cytokine and Chemokine Production, and Host Alloresponses
Gary A. Visner et al.
TRANSPLANTATION (2009)
Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis
Hisashi Oku et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?
T. M. Maher et al.
EUROPEAN RESPIRATORY JOURNAL (2007)
Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy chinese volunteers
Shaojun Shi et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK
J. Gribbin et al.
THORAX (2006)
Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts
H Zhou et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2005)
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis
A Azuma et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Expression of transforming growth factor beta (TGF-β1) in human epithelial alveolar cells:: a pro-inflammatory mediator independent pathway
KYC Kwong et al.
LIFE SCIENCES (2004)
Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis
T Kakugawa et al.
EUROPEAN RESPIRATORY JOURNAL (2004)
Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity
JW Card et al.
TOXICOLOGICAL SCIENCES (2003)
Inhibition of experimental acute pulmonary inflammation by pirfenidone
J Spond et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2003)
Pirfenidone effectively reverses experimental liver fibrosis
L García et al.
JOURNAL OF HEPATOLOGY (2002)
Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production
A Di Sario et al.
JOURNAL OF HEPATOLOGY (2002)
A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-α at the translational level
H Nakazato et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
Pirfenidone suppresses tumor necrosis factor-α, enhances interleukin-10 and protects mice from endotoxic shock
H Oku et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-β in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice
CB Keerthisingam et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis
AC Nicholson et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2000)
Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation
SN Iyer et al.
INFLAMMATION (2000)
Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals
HP Misra et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2000)
Share Paper
